Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Nat'l Exam for Physicians to Be Made More Accessible to the Handicapped
May 27, 2002
- Terumo: Sales Up 6.3% to \187,082 Mil.
May 27, 2002
- Wholesalers to Assist Makers in Immediate PMS
May 27, 2002
- General Risk Managers Appointed at All Nat'l Univ. Hospitals
May 27, 2002
- Olympus: New Digital Microscope "MIC-D"
May 27, 2002
- Drug Sales Up 3.5% in FY2001: CR&C
May 27, 2002
- GL on Subarachnoidal Hemorrhage Compiled
May 27, 2002
- AstraZeneca PLC: 1st Qtr Sales Up 13% to US$4,421 Mil.
May 27, 2002
- Otsuka Pharma Factory Sues Shionogi Claiming Infringement of Design Right
May 27, 2002
- Registration for J-WIND Increases Sharply
May 27, 2002
- Acarbose Prevents Type 2 Diabetes: STOP-NIDDM Study
May 27, 2002
- EPS Forms Alliance with VirtualeX for Subject Recruitment
May 27, 2002
- Mental Care Important for Atopic Dermatitis: ARC Seminar
May 27, 2002
- Novartis Opens Biomedical Research Center in US
May 27, 2002
- WEBSITE NEWS
May 27, 2002
- LWC to Undertake Survey on Lower Back Pain
May 27, 2002
- Novartis' Zometa to Be Approved for Bone Metastasis in the EU
May 27, 2002
- Teijin: Drug Sales, Operating Profits Up 6.7%, 7.0%
May 27, 2002
- Drug Terashima Joins AEON Welcia Stores
May 27, 2002
- Bayer AG: 1st Qtr Sales Down 6% to 7 Bil. Euro
May 27, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…